What is claimed is:

1. A bispecific antibody comprising a first antigen-binding domain that binds human CD3 and a second antigen-binding domain that binds a target antigen, wherein the first antigen-binding domain is derived from the antibody or antigen-binding fragment of an antibody that binds human CD3 with a binding dissociation equilibrium constant (K_D) of less than 2 nM as measured in a surface plasmon resonance assay at 25ºC in an antigen-capture format, wherein the first antigen-binding domain comprises six complementarity determining regions HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, respectively, selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, 20-22-24-28-30-32, 36-38-40-44-46-48, 52-54-56-60-62-64, 68-70-72-76-78-80, 84-86-88-92-94-96, 100-102-104-108-110-112, 116-118-120-124-126-128, 132-134-136-140-142-144, 148-150-152-156-158-160, 164-166-168-172-174-176, 180-182-184-188-190-192, 196-198-200-204-206-208, 212-214-216-220-222-224, 244-246-248-252-254-256, 260-262-264-268-270-272, 276-278-280-284-286-288, 292-294-296-300-302-304, 308-310-312-316-318-320, 324-326-328-332-334-336, 340-342-344-348-350-352, 356-358-360-364-366-368, 388-390-392-396-398-400, 404-406-408-412-414-416, 420-422-424-428-430-432, 436-438-440-444-446-448, 468-470-472-476-478-480, 484-486-488-492-494-496, 516-518-520-524-526-528, 596-598-600-604-606-608, 612-614-616-620-622-624, 628-630-632-636-638-640, 724-726-728-732-734-736, 772-774-776-780-782-784, 788-790-792-796-798-800, 804-806-808-812-814-816, 852-854-856-860-862-864, 884-886-888-892-894-896, 900-902-904-908-910-912, 932-934-936-940-942-944, 948-950-952-956-958-960, 1044-1046-1048-1236-1238-1240, 1052-1054-1056-1236-1238-1240, 1068-1070-1072-1236-1238-1240, 1076-1078-1080-1236-1238-1240, 1100-1102-1104-1236-1238-1240, 1108-1110-1112-1236-1238-1240, 1116-1118-1120-1236-1238-1240, 1124-1126-1128-1236-1238-1240, 1140-1142-1144-1236-1238-1240, 1148-1150-1152-1236-1238-1240, 1164-1166-1168-1236-1238-1240, and 1180-1182-1184-1236-1238-1240.

2. The bispecific antibody of claim 1, wherein the first antigen-binding domain comprises a heavy chain variable region/light chain variable region (HCVR/LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 594/602, 610/618, 626/634, 722/730, 770/778, 786/794, 802/810, 850/858, 882/890, 898/906, 930/938, 946/954, 1042/1234, 1050/1234, 1066/1234, 1074/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1162/1234, and 1178/1234.

3. The bispecific antibody of claim 1, that binds human CD3 with a K_D of less than 500 pM as measured in a surface plasmon resonance assay at 25ºC in an antigen-capture format, wherein the first antigen-binding domain comprises six complementarity determining regions HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, respectively, selected from the group consisting of SEQ ID NOs: 20-22-24-28-30-32, 36-38-40-44-46-48, 84-86-88-92-94-96, 100-102-104-108-110-112, 116-118-120-124-126-128, 132-134-136-140-142-144, 148-150-152-156-158-160, 164-166-168-172-174-176, 212-214-216-220-222-224, 244-246-248-252-254-256, 260-262-264-268-270-272, 276-278-280-284-286-288, 292-294-296-300-302-304, 308-310-312-316-318-320, 340-342-344-348-350-352, 356-358-360-364-366-368, 404-406-408-412-414-416, 420-422-424-428-430-432, 436-438-440-444-446-448, 484-486-488-492-494-496, 516-518-520-524-526-528, 724-726-728-732-734-736, 772-774-776-780-782-784, 788-790-792-796-798-800, 852-854-856-860-862-864, 884-886-888-892-894-896, 900-902-904-908-910-912, 932-934-936-940-942-944, 948-950-952-956-958-960, 1044-1046-1048-1236-1238-1240, 1052-1054-1056-1236-1238-1240, 1068-1070-1072-1236-1238-1240, 1076-1078-1080-1236-1238-1240, and 1100-1102-1104-1236-1238-1240.

4. The bispecific antibody of claim 3, that binds human CD3 with a K_D of less than 100 pM as measured in a surface plasmon resonance assay at 25ºC in an antigen-capture format, wherein the first antigen-binding domain comprises six complementarity determining regions HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, respectively, selected from the group consisting of SEQ ID NOs: 100-102-104-108-110-112, 116-118-120-124-126-128, 340-342-344-348-350-352, 356-358-360-364-366-368, 420-422-424-428-430-432, 484-486-488-492-494-496, 516-518-520-524-526-528, and 772-774-776-780-782-784.

5. The bispecific antibody of claim 1, wherein the antibody induces human T-cell proliferation and/or monkey T-cell proliferation *in vitro*, and wherein the first antigen-binding domain comprises six complementarity determining regions HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, respectively, selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, 116-118-120-124-126-128, 724-726-728-732-734-736, 772-774-776-780-782-784, 788-790-792-796-798-800, 804-806-808-812-814-816, 1044-1046-1048-1236-1238-1240, 1052-1054-1056-1236-1238-1240, 1068-1070-1072-1236-1238-1240, 1076-1078-1080-1236-1238-1240, 1100-1102-1104-1236-1238-1240, 1108-1110-1112-1236-1238-1240, 1116-1118-1120-1236-1238-1240, 1124-1126-1128-1236-1238-1240, 1140-1142-1144-1236-1238-1240, 1148-1150-1152-1236-1238-1240, 1164-1166-1168-1236-1238-1240, and 1180-1182-1184-1236-1238-1240.

6. The bispecific antibody of claim 7, wherein the first antigen-binding domain comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 722/730, 770/778, 786/794, 802/810, 1042/1234, 1050/1234, 1066/1234, 1074/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1162/1234, and 1178/1234.

7. The bispecific antibody of claim 1, wherein the first antigen-binding domain comprises six complementarity determining regions HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, respectively, comprising the amino acid sequences of 116-118-120-124-126-128.

8. The bispecific antibody of claim 1, wherein the first antigen-binding domain comprises six complementarity determining regions HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, respectively, comprising the amino acid sequences of 1108-1110-1112-1236-1238-1240.

9. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1-9, and a pharmaceutically acceptable carrier or diluent.

10. Use of the pharmaceutical composition of claim 9 in the manufacture of a medicament for upmodulating an immune response in a subject.

11. Use of the pharmaceutical composition of claim 9 in the manufacture of a medicament for treating a tumor in a subject.